HansBiomed Corporation Net Assets
HansBiomed Corporation net assets. Based on the latest financial reports, HansBiomed Corporation (042520) has net assets worth ₩33.89 Billion KRW (≈ $22.96 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩126.41 Billion ≈ $85.66 Million USD) and total liabilities (₩92.52 Billion ≈ $62.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 042520 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩33.89 Billion |
| % of Total Assets | 26.81% |
| Annual Growth Rate | 2.68% |
| 5-Year Change | -23.77% |
| 10-Year Change | -27.62% |
| Growth Volatility | 24.87 |
Net Assets of HansBiomed Corporation (2012–2025)
Net assets of HansBiomed Corporation from 2012 to 2025. This chart illustrates how HansBiomed Corporation's net assets have evolved over time, based on quarterly financial data. See 042520 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for HansBiomed Corporation (2012–2025)
The table below shows the annual net assets of HansBiomed Corporation from 2012 to 2025. For live market cap and overall valuation, see market value of HansBiomed Corporation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | ₩33.89 Billion ≈ $22.96 Million |
-49.52% |
| 2024-09-30 | ₩67.12 Billion ≈ $45.49 Million |
+34.38% |
| 2023-09-30 | ₩49.95 Billion ≈ $33.85 Million |
+9.46% |
| 2022-09-30 | ₩45.63 Billion ≈ $30.93 Million |
+2.66% |
| 2021-09-30 | ₩44.45 Billion ≈ $30.12 Million |
-26.33% |
| 2020-09-30 | ₩60.34 Billion ≈ $40.89 Million |
-28.23% |
| 2019-09-30 | ₩84.07 Billion ≈ $56.97 Million |
+28.74% |
| 2018-09-30 | ₩65.30 Billion ≈ $44.26 Million |
+21.54% |
| 2017-09-30 | ₩53.73 Billion ≈ $36.41 Million |
+14.76% |
| 2016-09-30 | ₩46.82 Billion ≈ $31.73 Million |
+8.48% |
| 2015-09-30 | ₩43.16 Billion ≈ $29.25 Million |
+9.57% |
| 2014-09-30 | ₩39.39 Billion ≈ $26.69 Million |
+34.39% |
| 2013-09-30 | ₩29.31 Billion ≈ $19.86 Million |
+21.93% |
| 2012-09-30 | ₩24.04 Billion ≈ $16.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HansBiomed Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4632317198000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
HansBiomed Corporation Net Assets Breakdown (September 2025)
HansBiomed Corporation net assets breakdown by equity component as of September 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩80.03 Billion | 237.44% |
| Total Equity | ₩33.70 Billion | 100.00% |
HansBiomed Corporation Competitors by Market Cap
The table below lists competitors of HansBiomed Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ANDHRA PAPER LIMITED
NSE:ANDHRAPAP
|
$136.43 Million |
|
6K Additive Inc
AU:6KA
|
$136.43 Million |
|
Wintermar Offshore Marine Tbk
JK:WINS
|
$136.43 Million |
|
Thessaloniki Water Supply & Sewerage Co S.A
AT:EYAPS
|
$136.49 Million |
|
eGain Corporation
NASDAQ:EGAN
|
$136.36 Million |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
$136.29 Million |
|
Excelliance MOS
TWO:5299
|
$136.28 Million |
|
Eimco Elecon (India) Limited
NSE:EIMCOELECO
|
$136.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HansBiomed Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 66,874,048,790 to 33,703,812,120, a change of -33,170,236,670 (-49.6%).
- Net loss of 31,341,350,190 reduced equity.
- Other factors decreased equity by 1,828,886,480.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-31.34 Billion | -92.99% |
| Other Changes | ₩-1.83 Billion | -5.43% |
| Total Change | ₩- | -49.60% |
Book Value vs Market Value Analysis
This analysis compares HansBiomed Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.97x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.12x to 5.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-09-30 | ₩4971.46 | ₩15500.00 | x |
| 2017-09-30 | ₩5705.36 | ₩15500.00 | x |
| 2018-09-30 | ₩6651.25 | ₩15500.00 | x |
| 2019-09-30 | ₩7592.23 | ₩15500.00 | x |
| 2020-09-30 | ₩6026.47 | ₩15500.00 | x |
| 2021-09-30 | ₩4439.82 | ₩15500.00 | x |
| 2022-09-30 | ₩4732.02 | ₩15500.00 | x |
| 2023-09-30 | ₩4243.81 | ₩15500.00 | x |
| 2024-09-30 | ₩5149.32 | ₩15500.00 | x |
| 2025-09-30 | ₩2595.20 | ₩15500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HansBiomed Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -34.91%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 3.75x
- Recent ROE (-92.99%) is below the historical average (-8.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 10.48% | 14.33% | 0.65x | 1.13x | ₩114.52 Million |
| 2013 | 11.72% | 17.11% | 0.60x | 1.14x | ₩503.04 Million |
| 2014 | 8.88% | 16.63% | 0.47x | 1.13x | ₩-441.46 Million |
| 2015 | 11.38% | 20.96% | 0.45x | 1.21x | ₩593.61 Million |
| 2016 | 9.88% | 15.92% | 0.45x | 1.38x | ₩-56.66 Million |
| 2017 | 14.57% | 20.04% | 0.49x | 1.49x | ₩2.46 Billion |
| 2018 | 6.15% | 7.76% | 0.56x | 1.41x | ₩-2.51 Billion |
| 2019 | 13.29% | 14.85% | 0.50x | 1.79x | ₩2.46 Billion |
| 2020 | -29.57% | -22.27% | 0.61x | 2.18x | ₩-23.87 Billion |
| 2021 | -41.14% | -30.95% | 0.46x | 2.91x | ₩-22.73 Billion |
| 2022 | 13.47% | 8.26% | 0.57x | 2.89x | ₩1.58 Billion |
| 2023 | -46.91% | -29.53% | 0.64x | 2.49x | ₩-27.96 Billion |
| 2024 | -10.80% | -8.90% | 0.67x | 1.82x | ₩-13.91 Billion |
| 2025 | -92.99% | -34.91% | 0.71x | 3.75x | ₩-34.71 Billion |
Industry Comparison
This section compares HansBiomed Corporation's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $146,559,788,209
- Average return on equity (ROE) among peers: 9.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HansBiomed Corporation (042520) | ₩33.89 Billion | 10.48% | 2.73x | $136.42 Million |
| Shinhung (004080) | $106.86 Billion | 7.92% | 0.32x | $91.86 Million |
| JVM Co. Ltd (054950) | $112.17 Billion | 9.89% | 0.57x | $188.89 Million |
| U&I Corporation (056090) | $28.54 Billion | -17.41% | 1.63x | $313.85 Million |
| Huvitz Co. Ltd (065510) | $78.48 Billion | -3.47% | 0.98x | $46.00 Million |
| Vieworks Co. Ltd (100120) | $126.17 Billion | 15.56% | 0.09x | $176.92 Million |
| Corentec Co Ltd (104540) | $56.27 Billion | -1.53% | 0.27x | $42.50 Million |
| SD Biosensor Inc (137310) | $757.55 Billion | 81.27% | 0.93x | $518.00 Million |
| Hironic Co. Ltd (149980) | $37.75 Billion | -0.69% | 0.14x | $39.75 Million |
| Humasis Co. Ltd (205470) | $15.24 Billion | -8.04% | 1.39x | $172.92 Million |
About HansBiomed Corporation
HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralize… Read more